@FierceBiotech: AstraZeneca bolts together a top transatlantic team for CRISPR R&D. Report | Follow @FierceBiotech
@JohnCFierce: If you contrast the $NVS approach to CRISPR and $AZN's, $NVS seems much more focused. | Follow @JohnCFierce
@DamianFierce: Christoph Westphal's Flex Pharma prices an $86.4M IPO. News | Follow @DamianFierce
> Celgene ($CELG) put out its 2014 results today, noting that R&D expenses surged to $2.4 billion last year, up from $2.2 billion in 2013. Increased clinical trial activity was fingered for much of the increase. Celgene has one of the most active partnering groups in the industry. Release
> While the biotech IPO window remains open, not all companies can squeeze through. Kolltan Pharmaceuticals bowed out of its planned $86 million debut, designed to support its early-stage work on antibodies directed at receptor tyrosine kinases. Story
Medical Device News
@FierceMedDev: ICYMI yesterday: Abiomed shares hit all-time high due to strong demand for its Impella heart pumps. Article | Follow @FierceMedDev
@EmilyWFierce: Gilead zooms past AbbVie in hep C race with UnitedHealth deal. More | Follow @EmilyWFierce
> 2015 med tech IPO kick-off: Entellus exceeds expectations, while Presbia gets the deal done. Article
> China FDA approves Agilent's microarray scanner for in vitro diagnostics. Story
> Philips and Teva unveil new med tech incubator in Israel. Report
Pharma News
@FiercePharma: GSK to divest meningitis shots in exchange for EU clearance of Novartis deal. More from FierceVaccines | Follow @FiercePharma
@EricPFierce: Do you want to know about the newest stents or heart valves approved by the FDA in 2014. Read on. Feature | Follow @EricPFierce
> Ex-FDA chief testifies against J&J in Risperdal liability case. More
> Looking to get out of the hot seat, Salix to restate financials for past 7 quarters. Story
> Gilead zooms past AbbVie in hep C race with UnitedHealth deal. Report
> Trans-Pacific trade talks on biologics not even close to agreement: USTR. Article
Vaccines News
> Novartis' Bexsero picks up FDA nod--but with competition looming, approval isn't everything. Article
> Pfizer's Prevenar price cut 'inadequate,' critics say. More
> Serum threatens Merck's Gardasil with low-cost competitor. Story
> First batch of GSK/NIH Ebola candidate shipped for Phase III trial in Liberia. Report
> GSK to divest meningitis shots in exchange for EU clearance of Novartis deal. Item
Pharma Manufacturing News
> Chinese Pharmacopoeia venture up and running as safety push continues. More
> AmerisourceBergen again reports big leaps in revenue and earnings. Report
> GSK awards contract for API plant in Scotland. News
> International regulators offer to help India build expertise. Story
> Ranbaxy earnings pulled back down by manufacturing issues. Article